Sagimet Biosciences Inc. (SGMT)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on SGMT

With Tiblio's Option Bot, you can configure your own wheel strategy including SGMT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SGMT
  • Rev/Share 0.0
  • Book/Share 4.3171
  • PB 1.1072
  • Debt/Equity 0.0003
  • CurrentRatio 20.3443
  • ROIC -0.4715

 

  • MktCap 146625802.0
  • FreeCF/Share -1.5767
  • PFCF -2.8884
  • PE -2.6945
  • Debt/Assets 0.0003
  • DivYield 0
  • ROE -0.3521

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SGMT Oppenheimer -- Outperform -- $30 Dec. 6, 2024

News

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567
SGMT
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Positive

Sagimet Biosciences' partner Ascletis reported strong phase 3 results for denifanstat in moderate-to-severe acne, validating FASN inhibition as a novel oral treatment. Sagimet is advancing next-gen FASN inhibitor TVB-3567 for U.S. acne trials and planning a phase 1b combo study with denifanstat and resmetirom for MASH. The acne market is large and underserved, while FASN inhibition offers potential in both dermatology and metabolic disease, expanding SGMT's addressable market.

Read More
image for news Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
SGMT
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Thursday, May 29, 2025 at 1:00 PM ET.

Read More
image for news Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
SGMT
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026

Read More
image for news Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

About Sagimet Biosciences Inc. (SGMT)

  • IPO Date 2023-07-17
  • Website https://sagimet.com
  • Industry Biotechnology
  • CEO Mr. David A. Happel
  • Employees 14
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.